Skip to main content

Table 4 Relationship between seizure characteristics and QOLIE-31 domains

From: Determinants of quality of life in Nigerian female patients with epilepsy on carbamazepine and levetiracetam monotherapy

Variables

Seizure worry

Overall quality of life

Emotional well-being

Energy

Cognitive functioning

Medication effects

Social functioning

Duration of epilepsyb

  < 2yrs

52.31(13.94)

65.65(22.73)

52.70(12.46)

51.52(11.22)

52.55(17.08)

60.63(22.57)

58.17(24.97)

  ≥ 2yrs

49.53(18.51)

51.24(20.30)

49.45(13.28)

49.42(13.28)

45.32(15.37)

46.92(24.68)

46.50(18.15)

 p value

0.508

0.005*

0.300

0.360

0.056

0.019*

0.015

Family history of epilepsyb

 Yes

40.26(17.52)

54.64(15.31)

47.14(12.47)

47.14(8.25)

38.81(15.77)

45.83(18.71)

41.07(13.32)

 No

51.79(17.10)

54.54(22.57)

50.70(13.21)

50.35(9.82)

48.31(15.71)

50.76(25.66)

50.50(21.09)

 p value

0.022*

0.987

0.349

0.250

0.038*

0.493

0.109

Last episode of seizurea

 Nil

56.77(11.18)

50.83(15.88)

45.33(2.31)

36.67(5.77)

45.46(1.29)

63.88(4.81)

64.67(5.77)

  < 6 months

46.58(18.45)

53.50(22.19)

47.20(12.88)g

50.17(9.61)

45.13(16.26)

52.22(24.24)

46.39(21.28)

 6 months–1 year

54.92(16.04)

58.10(22.35)

57.20(12.57)

51.50(9.21)

49.87(17.20)

48.21(26.74)

53.50(19.62)

 2–5 years

57.76(10.61)

50.00(16.83)

48.00(9.24)

46.43(9.45)

51.10(9.34)

33.73(20.70)

48.00(15.58)

 p value

0.090

0.724

0.005*

0.057

0.523

0.205

0.240

Aetiologya

 Structural

51.26(17.65)

50.82(19.77)

49.16(13.15)

49.45(8.85)

46.69(15.71)

48.52(24.47)

48.04(19.43)

 Metabolic

61.45(12.68)

78.33(19.09)

66.67(9.24)

51.67(12.58)

59.08(13.64)

70.38(17.65)

63.40(30.89)

 Immune

64.00(0.00)

45.00(0.00)

68.00(0.00)

55.00(0.00)

54.45(0.00)

19.43(0.00)

43.00(0.00)

 Unknown

47.56(17.60)

58.06(23.16)

49.95(12.56)

50.24(10.72)

46.30(16.64)

51.42(25.24)

49.83(21.30)

 p value

0.399

0.086

0.071

0.910

0.573

0.277

0.629

Seizure typea

 Focal

51.52(18.67)

53.44(21.43)

49.50(15.45)

46.56(10.60)

43.42(17.11)

49.83(24.42)

47.76(17.79)

 Generalized

50.60(17.41)

57.13(22.51)

52.75(14.53)

50.94(9.46)

50.64(16.41)

49.65(26.91)

52.19(23.10)

 FBTC

48.80(18.64)

54.75(20.70)

49.60(11.49)

50.00(9.74)

44.86(15.71)

52.83(23.57)

47.85(18.40)

 Unknown/unclassified

51.82(13.92)

48.54(24.11)

46.33(10.98)

51.25(8.56)

49.05(13.68)

42.36(24.74)

47.50(23.84)

 p value

0.929

0.706

0.502

0.476

0.340

0.651

0.800

EEG frequency

 Fast

52.75(16.16)

61.79(24.97)

55.33(13.88)

51.79(9.87)

51.83(17.05)

56.68(29.07)

53.36(23.26)

 Slow

48.30(18.38)

49.31(17.28)

46.48(11.23)

48.53(9.32)

43.47(14.31)

45.29(20.09)

46.16(17.63)

 p value

0.212

0.004*

0.001*

0.096

0.009*

0.023*

0.081

Epileptiform pattern

 Nil

54.08(17.30)

52.86(20.94)

46.86(13.54)

52.86(8.25)

49.98(15.86)

42.80(30.21)

49.07(25.25)

 Focal

52.89(17.74)

56.98(24.06)

54.29(13.02)p

50.83(9.62)

49.51(15.64)

56.81(23.83)

52.10(19.95)

 Generalized

46.34(17.04)

52.78(19.59)

47.36(12.26)

48.07(9.90)

43.62(16.07)

45.96(22.76)

46.43(19.21)

 p value

0.149

0.640

0.028*

0.193

0.176

0.062

0.440

  1. aANOVA with Tukey’s HSD
  2. bIndependent t-test
  3. d15–25 significantly different at p < 0.05 compared to ages 26–35 years
  4. ePrimary significantly different at p < 0.05 compared to tertiary and Postgraduate
  5. fSecondary significantly different at p < 0.05 compared to Postgraduate
  6. g< 6 months significantly different at p < 0.05 compared to 6 months–1 year
  7. pFocal significantly different at p < 0.05 compared to generalized
  8. *Statically significant, CBM carbamazepine, LTM levetiracetam